This Phase I trial is evaluating appropriate dosing levels of an intratumoral therapy (within a tumour) alone, and in combination with immunotherapy (pembrolizumab) in people with advanced solid cancers.
This trial is treating patients with advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of ReoCure as Monotherapy and in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours
This is a dose escalation and dose expansion trial. In Part A (ReoCure Monotherapy Dose Escalation) will assess ReoCure at 3 different dose levels. Participants will receive 1 injection every 3 weeks in 3 Cohorts. Part B (ReoCure Combination Therapy Dose Escalation) will test 2 dose levels of ReoCure in combination with fixed dose of pembrolizumab (200mg every 3 weeks) in 2 cohorts. For the Dose Expansion part of the study, ReoCure in combination with a fixed dose of pembrolizumab (200mg once in every 3 weeks) treated with the recommended dose selected from the Dose Escalation part. It is hoped that this study will determine the safest and most effective dose of ReoCure for those with advanced or late stage cancer, and help provide more insight in the effect of ReoCure.
Recruiting Hospitals Read More